Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Researchers in Denmark conducted a prospective single-centre study including 160 patients with newly diagnosed high-risk prostate cancer between 2021 and 2024. All the participants first underwent an ...

A new study from Denmark shows for the first time that men with biochemically recurrent prostate cancer who undergo PSMA PET/CT before salvage radiotherapy have improved survival rates compared to ...

Visual Abstract. Overall survival for patients treated with salvage radiotherapy: real world data from an entire country. A patient with biochemical recurrence after radical prostatectomy and no ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether ...

A new radioactive diagnostic agent for use in prostate cancer has been approved by the US Food and Drug Administration (FDA). The product, Gallium 68 PSMA-11 (Ga 68 PSMA-11), has been approved for ...

Surgery patients staged with PSMA-PET appear to have a lower risk of early BCR than those staged with conventional imaging. Early oncologic outcomes after radical prostatectomy (RP) for very high risk ...

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 ...

Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy The abstract presents a favorable safety ...